Fingerprint
Dive into the research topics of 'Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically